Comparison of efficacy in continuous hemodiafiltration (CHDF) therapy for acute renal failure between polysulfone membrane and polymethyl methacrylate membrane

Continuous venovenous hemodiafiltration for renal failure and sepsis.

Comparison of continuous and intermittent renal replacement therapy for acute renal failure.

BACKGROUND Mortality rates of critically ill patients with acute renal failure (ARF) requiring renal replacement therapy (RRT) are high. Intermittent and continuous RRT are available for these patients on the intensive care units (ICUs). It is unknown which technique is superior with respect to patient outcome. METHODS We randomized 125 patients to treatment with either continuous venovenous ...

Continuous venovenous hemodiafiltration increased survival more than did continuous hemofiltration in acute renal failure.

M e t h o d s Design: Randomized controlled trial. Allocation: Concealed.* Blinding: Unblinded.* Follow-up period: 90 days. Setting: Intensive care units (ICUs) in Geneva, Switzerland. Patients: 206 patients (mean age 63 y, 61% men) with acute renal failure (urine output < 200 mL/12 h despite treatment or blood urea nitrogen > 30 mmol/L with urine output < 1500 mL/12 h). Exclusion criteria were...

Vitamin E-Coated Polysulfone Membrane-Based Hemodiafiltration Attenuates Inflammation in a Rat Model of Lipopolysaccharide-Induced Systemic Inflammation

Background: Acute blood purification (ABP) therapy is used regularly in the clinical setting and reportedly alleviates organ failure associated with severe systemic inflammatory responses, leading to reduced mortality. The present study aimed to determine whether there is a difference in efficacy between polysulfone (PS) membranes, which are currently used regularly in the clinical setting, and...

Continuous renal replacement therapy in acute renal failure.

The management of acute renal failure in the critically ill patient is extremely variable and there are no published standards for the provision of renal replacement therapy in this population. Continuous renal replacement therapy seems to be the treatment of choice because of its superior metabolic and hemodynamic control. There is better organ protection by continuous treatment but no evidenc...